16 September 2026 editorial review · Trial
SAFEGUARD: SAB-142, a fully human anti-thymocyte globulin, in new-onset stage-3 T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Added current PartC24month endpoint, corrected15-year-olds described asadults and qualified cross-trialcomparability/powerclaim.
Registry: NCT07187531. Endpoint reviewed: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) (From dose administration through Week 4); Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) (From dose administration up to Month 12); Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT). (Baseline and Month 24). Eligibility reviewed: Age 5 Years to 40 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.